FDA approves Radius Health's TYMLOS(TM) (abaloparatide)
Radius Health announced the FDA has approved TYMLOS (abaloparatide) injection for treatment of postmenopausal women with osteoporosis at high risk for fracture defined as history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed osteoporosis therapy. April 28, 2017